Recognition and management of systemic lupus erythematosus

Drugs

Volumn 54, Issue 3, 1997, Pages 422-434

  Schroeder, Johann O ^a   Euler, Hans H ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT;

CENTRAL NERVOUS SYSTEM DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PROGNOSIS; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030827711     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754030-00005     Document Type: Review

References (117)

1. Mills JA. Systemic lupus erythematosus [review]. N Engl J Med 1994; 330: 1871-9
2. Boumpas DT, Austin HA, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts. Part 1 : renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease [review]. Ann Intern Med 1995; 122: 940-50
3. Boumpas DT, Fessler BJ, Austin HA, et al. Systemic lupus erythematosus: emerging concepts. Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis [review]. Ann Intern Med 1995; 123: 42-53
4. Hochberg MC. Systemic lupus erythematosus (review). Rheum Dis Clin Am 1990; 16: 617-39
5. McCarty DJ, Manzi S, Medsger Jr TA, et al. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995; 38: 1260-70
6. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1.000 patients. Medicine 1993; 72: 113-24
7. Theofilopoulos AN. Mechanisms and genetics of autoimmunity [review]. Immunol Today 1995; 16: 90-8
8. van Es JH, Gmelig-Meyling FH, Akker van de WR, et al. Somatic mutations in the variable regions of a human IgG antidouble-stranded DNA autoantibody suggests a role for antigen in the induction of systemic lupus erythematosus. J Exp Med 1991; 173: 461-70
9. Davies KA. Complement, immune complexes and systemic lupus erythematosus. Br J Rheumatol 1996; 35: 5-23
10. Duits AJ, Bootsma H, Derksen RHWM, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995; 38: 1832-6
11. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-8
12. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7
13. Passas CM, Wong RL, Peterson M, et al. A comparison of the specificity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1985; 28: 620-3
14. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases [review]. Semin Arthritis Rheum 1995; 24: 323-58
15. Elkon KB. Systemic lupus erythematosus: autoantihodies in SLE. In: Klippel JH, Dieppe PA, editors. Rheumatology. St Louis: Mosby, 1994; 6.4.1-10
16. Olhoffer IH, Peng SL, Craft J. Revisiting autoantibody profiles in systemic lupus erythematosus. J Rheumatol 1997; 24: 297-302
17. Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1483-90
18. Panush RS, Greer JM, Morshedian KK. What is lupus? What is not lupus [review]? Rheum Dis Clin North Am 1993; 19: 223-34
19. Calvo-Alén J, Bastian HM, Straaton KV, et al. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum 1995; 38: 1475-84
20. Schur PH. Clinical features of SLE. In: Kelly WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1993: 1017-42
21. Gladman DD, Urowitz MB. Systemic lupus erythematosus: Clinical features. In: Klippel JH, Dieppe PA, editors. Rheumatology. St Louis: Mosby, 1994: 6.2.1-20
22. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. BMJ 1983; 287: 1088-9
23. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4
24. Roubey RAS. Immunology of the antiphospholipid antibody syndrome [review]. Arthritis Rheum 1996; 39: 1444-54
25. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antihody syndrome. N Engl J Med 1995; 332: 993-7
26. Stafford-Brady FJ, Urowitz MB, Gladman DD, et al. Lupus retinopathy: patterns, associations, and prognosis. Arthritis Rheum 1988; 31: 1105-10
27. Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. I: Outcome and survival. Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 447-54
28. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic-lupus erythematosus: negative impact of increasing age at onset, Black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33: 37-48
29. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcome. Arthritis Rheum 1995; 38: 274-83
30. Ahu-Shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in systemic lupus erythematosus: results from a single center. I: causes of death. J Rheumatol 1995; 22: 1259-64
31. Kashgarian M. Lupus nephritis: lessons from the path lab [review]. Kidney Int 1994; 45: 928-38
32. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989; 32: 1107-18
33. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 352: 630-40
34. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1995; 39: 363-9
35. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus [published erratum appears in Lancet 1995; 346: 516]. Lancet 1995; 345: 1595-9
36. Manzi S, Rairie JE, Carpenter AB, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996; 39: 1178-88
37. Esdaile JM, Abrahamowicz M, Joseph L, et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 370-8
38. Steinberg AD, Gourley MF, Klinman DM, et al. NIH Conference: systemic lupus erythematosus. Ann Intern Med 1991; 115: 548-59
39. Ginzler EM, Felson DT, Anthony JM, et al. Hypertension increases the risk of renal deterioration in systemic lupus erythemalosus. J Rheumatol 1993; 20: 1694-1700
40. Leong KH, Koh ET, Feng PH, et al. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 1264-7
41. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 315: 1424-30
42. Pryor BD, Bologna SG, Kahl L. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1475-82
43. Kimberly RP. Corticosteroids and anti-inflammalory drugs [review]. Rheum Dis Clin North Am 1988; 14: 203-21
44. Wallace DJ, Metzger AL, Klinenberg JR, et al. NSAID usage patterns by rheumatologists in the treatment of SLE. J Rheumatol 1989; 16: 557-60
45. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-9
46. Bouland DL, Specht NL, Hegstad DR. Ibuprofen and aseptic meningitis [letter]. Ann Intern Med 1986; 104: 731
47. Albert DA, Hadler NM, Ropes MW. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum 1979; 22: 945-53
48. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945-50
49. Boumpus DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5
50. Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996; 125: 549-57
51. Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21: 1457-62
52. Wallace DJ. Antimalarial agents and lupus [review]. Rheum Dis Clin North Am 1994; 20: 243-63
53. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. M Engl J Med 1991; 324: 150-4
54. Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroqume use and the development of retinal toxicily. J Rheumatol 1985; 12: 692-4
55. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J 1992; 85: 274-9
56. Spalton DJ, Verdon Roe GM, Hughes GR. Hydroxychloroquine, dosage parameters and retinopathy. Lupus 1993; 2: 355-8
57. Easterbrook M. The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 1993; 23 (2 Suppl. 1): 62-7
58. Mazzuca SA, Yung R, Brandt KD, et al. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol 1994; 21: 59-63
59. Falcone PM, Paolini L, Lou PL, Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol 1993; 25: 385-8
60. Sztejnbok M, Stewart A, Diamond H, et al. Azathioprine in the treatment of systemic lupus erythematosus: a controlled study. Arthritis Rheum 1971; 14: 639-45
61. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984; 311: 1528-33
62. Cummins D, Sekar M, Halil O, et al. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996; 61: 1661-2
63. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis Rheum 1981; 24: 648-50
64. Kinlen LJ, Peto J, Doll R, et al. Cancer in patients treated with immunosuppressive drugs [letter]. BMJ 1981; 282: 474
65. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988-92
66. Austin HA, 3d. Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9
67. Valeri A, Radhakrishnan J, Estes D, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-8
68. McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423-31
69. Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatrie systemic lupus erythematosus. Am J Med 1995; 98: 32-41
70. Boulware DW, Makkena R, Monthly cyclophosphamide in lupus pneumonitis and myositis [letter]. J Rheumatol 1991; 18: 153
71. Eiser AR, Shanies HM. Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 1994; 37: 428-31
72. Fukuda M, Kamiyama Y, Kawahara K, et al. The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus. Eur J Pediatr 1994; 153: 167-70
73. Boumpas DT, Barez S, Klippel JH, et al. Intermittent cyclophosphamide for the treatment of autoimmune ibrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112: 674-7
74. Boumpas DT, Austin III HA, Vaughn EM, et al. Risk for sustained umenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9
75. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524-30
76. Huffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98
77. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study. Arthritis Rheum 1995; 38: 1120-7
78. Klippel JH. Cyclophosphamide: ovarian and other toxicities [editorial]. Lupus 1995 Feb: 4 (1): 1-2
79. Klippel JH. Systemic lupus erythematosus: treatment-related complications superimposed on chronic disease. JAMA 1990; 263: 1812-5
80. Wallace DJ. Successful use of nitrogen mustard for cyclophosphamide resistant diffuse proliferative glomerulonephritis: report of 2 cases [letter]. J Rheumatol 1995; 22: 801-2
81. Patapanian H, Graham S, Sambrook PN, et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 1988; 27: 44-7
82. Jones JV. Plasmapheresis in SLE. Clin Rheum Dis 1982; 8: 243-60
83. Wei N, Klippel JH, Huston DP, et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983; 1: 17-22
84. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1374-9
85. Schroeder JO, Euler HH, Löffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987; 107: 344-6
86. Euler HH, Schroeder JO. Antibody depletion and cytotoxic drug therapy in severe systemic lupus erythematosus. Transfus Sci 1992; 13: 167-84
87. Euler HH, Schroeder JO, Harten P, et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37: 1784-94
88. Kremer JM. The changing face of therapy for rheumatoid arthritis [review]. Rheum Dis Clin North Am 1995; 21: 845-52
89. Huffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82
90. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13
91. Wilke WS, Krall PL, Scheetz RJ, et al. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991; 9: 581-7
92. Walz LeBlanc BA, Dagenais P, Urowitz MB, et al. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 836-8
93. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 1674-7
94. Radhakrishnan J, Kunis CL, D'Agati V, et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-54
95. Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37: 551-8
96. Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996; 35: 669-75
97. Hiepe F, Volk HD, Apostoloff E, et al. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 1991; 338: 1529-30
98. Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autoloeous stem cell transplantation. Blood 1996 Nov; 88 (9): 3621-5
99. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7
100. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000
101. Maier WR Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thromhocytopenia. Arthritis Rheum 1990; 33: 1233-9
102. Schroeder JO, Zeuner RA, Euler HH, et al. High dose intravenous immunoglobulins in systemic lupus erythemalosus: clinical and serological results of a pilot studs. J Rheumatol 1996; 23: 71-5
103. Francioni C, Galeazzi M, Fioravanti A, et al. Long term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 163-8
104. Schifferli JA, Leski M, Favre H, et al. High-dose intravenous IgG treatment and renal function. Lancet 1991; 337: 457-8
105. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-34
106. Pasatiempo AM, Kroser JA, Rudnick M, et al. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21: 347-9
107. Tan K, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy Arch Neurol 1993; 50: 137-9
108. Cunninghain-Rundles C, Zhou Z, Mankariuus S, et al. Long-term use of IgA-depleted intravenous imimmoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272-8
109. Vollenhoven van RF, Engleman EG, McGuire JL. Dehydromepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 1826-31
110. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thromhocytopenia in systemic lupus erythematosus. Ann Intern Med 1988; 108: 703-6
111. Callen JP. Treatment of cutaneous lesions in patients with lupus erythematosus [review]. Dermatol Clin 1994; 12: 201-6
112. Byrd SR, Gelber RH. Effect on dapsone on haemoglobin concentration in patients with leprosy. Lepr Rev 1991; 62: 171-8
113. Rudzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992 Nov; 127 (5): 513-8
114. Nau H. Retinoid teratogenesis: toxicokinetics and structure-specificity [review]. Arch Toxicol Suppl 1944; 16: 118-27
115. Petri M. Systemic lupus erythematosus and pregnancy. [review]. Rheum Dis Clin North Am 1994; 20: 87-118
116. Bermas BL, Hill JA. Effects of imniunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38: 1722-32
117. Buchanan NMM, Toubi E, Khamashta MA, et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486-8